The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application ...

The injectable prescription medicine is primarily used to treat type 2 diabetes ... exercise, improved diet and optimal sleep, Siegel said. "Having said that, these weight-loss drugs (including ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

A once-daily oral GLP-1 conferred greater reductions in HbA1c and body weight than placebo among adults with type 2 diabetes, ...

In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

Loss of skeletal muscle mass is a known risk factor for falls. Researchers from the University of Tsukuba conducted a 5-yr follow-up study on 471 patients with type 2 diabetes and found that ...

Certain diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are associated with weight ... dietary and exercise interventions to mitigate muscle loss and reduce ...